Skip to main content
SpringerLink
Log in

Nasopharyngeal Cancer

  • Chapter
  • First Online:
Handbook of Evidence-Based Radiation Oncology

  • 2681 Accesses

Abstract

This chapter will discuss epidemiology, workup, and management of nasopharyngeal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310–7.

    Article  CAS  Google Scholar 

  • Blanchard P, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55.

    Article  Google Scholar 

  • Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, Choi PH, Johnson PJ. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology. Biology. Physics. 1995 Oct 15;33(3):569–77.

    Article  CAS  Google Scholar 

  • Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005b;97:536–9.

    Article  CAS  Google Scholar 

  • Chen L, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13(2):163–71. Available at: https://doi.org/10.1016/S1470-2045(11)70320-5.

    Article  Google Scholar 

  • Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998;83:2270–83.

    Article  CAS  Google Scholar 

  • Garden AS. The nasopharynx. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 8th ed. St. Louis: Mosby; 2003. p. 178–95.

    Google Scholar 

  • International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Phys. 1996;35:463–9.

    Article  Google Scholar 

  • Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873–9.

    Article  Google Scholar 

  • Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12–22.

    Article  Google Scholar 

  • Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57:49–60.

    Article  Google Scholar 

  • Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.

    Article  Google Scholar 

  • Lee AWM, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol. 2011;98(1):15–22.

    Article  Google Scholar 

  • Lee AWM, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr. Cancer. 2015;121(8):1328–38.

    Article  Google Scholar 

  • Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2008;24:5414–8.

    Article  Google Scholar 

  • Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461–70.

    Article  CAS  Google Scholar 

  • Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350–7.

    Article  CAS  Google Scholar 

  • Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981–91.

    Article  Google Scholar 

  • Sun Y, Yu XL, Luo W, et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngealcarcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol. 2014;110(3):390–7.

    Article  Google Scholar 

  • Sun Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.

    Article  CAS  Google Scholar 

  • Wang W-Y, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119(5):963–70.

    Article  CAS  Google Scholar 

  • Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

We thank Gautam Prasad, MD, PhD; James Rembert, MD; and Eric K. Hansen, MD, for their work on the prior edition of this chapter.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

    Jason Chan & Sue S. Yom

Authors
  1. Jason Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sue S. Yom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason Chan .

Editor information

Editors and Affiliations

  1. The Oregon Clinic, Providence St. Vincent Medical Center, Portland, OR, USA

    Eric K. Hansen

  2. Department of Radiation Oncology, University of California, San Franc, SAN FRANCISCO, CA, USA

    Mack Roach III

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chan, J., Yom, S.S. (2018). Nasopharyngeal Cancer. In: Hansen, E., Roach III, M. (eds) Handbook of Evidence-Based Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-62642-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62642-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62641-3

  • Online ISBN: 978-3-319-62642-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation